PanCareLIFE Publications
PanCareLIFE was a 5-year (2013-8) EU Framework 7 Programme in the Health Theme that studied the impact of treatment regimes on the long-term health of childhood cancer survivors. Specifically, PanCareLIFE evaluated the risks of impairments in female fertility, in hearing, and in quality of life. PanCareLIFE also developed two guidelines for fertility preservation, and will disseminate widely the results from this project. Below an overview of publications that were made within the PanCareLIFE project.
| Title | Authors | Link | |
|---|---|---|---|
| Genetic variation in gonadal impairment in female survivors of childhood cancer: design of a PanCareLIFE study. | van der Kooi ALF et al. | BMC Cancer 18, 930. https://doi.org/10.1186/s12885-018-4834-3 |
|
| PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity, and health related quality of life after cancer occurring among children and adolescents. | Byrne J et al. | Eur J Cancer 103, 227-237, 2018. https://doi.org/10.1016/j.ejca.2018.08.007 |
|
| Fertility Among Female Survivors of Childhood, Adolescent, and Young Adult Cancer: Protocol for Two Pan-European Studies (PanCareLIFE). | van den Berg M et al. | JMIR Res Protoc 7, e10824, 2018. https://doi.org/10.2196%2F10824 |
|
| Genetic determinants of ototoxicity during and after childhood cancer treatment: protocol for the PanCareLIFE study. | Clemens E et al. | JMIR Res Protoc 8, e11868, 2019. https://doi.org/10.2196%2F11868 |
|
| Genetic variation of cisplatin-induced ototoxicity in non-cranial-irradiated pediatric patients using a candidate gene approach: The International PanCareLIFE Study. | Clemens E et al. | Pharmacogenomics J 20, 294–305, 2020. https://doi.org/10.1038/s41397-019-0113-1 |
|
| Association of candidate pharmacogenetic markers with platinum-induced ototoxicity: PanCareLIFE dataset. | Langer T et al. | Data in Brief 32:106227, 2020. https://doi.org/10.1016/j.dib.2020.106227 |
|
| Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study. | Langer T et al. | Eur J Cancer. 138, 212-224, 2020. https://doi.org/10.1016/j.ejca.2020.07.019 |
|
| Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function, | van der Kooi ALF et al. | Human Reproduction deaa342, 2021. https://doi.org/10.1093/humrep/deaa342. |
|
| Health-related quality of life in European childhood cancer survivors: protocol for a study within PanCareLIFE . | Calaminus G et al. | JMIR Res Protoc 2021, 10: e21851 https://doi.org/10.2196/21851 |
|
| Treatment-related fertility impairment in long-term female childhood, adolescent and young adult cancer survivors: investigating dose-effect relationships in a European case-control study (PanCareLIFE). | van den Berg H et al. | Human Reproduction 0:1–13. 2021. https://doi.org/10.1093/humrep/deab035 |
|
| Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. | Mulder RL et al. | The Lancet Oncology 22, e45 – e56, 2021. https://doi.org/10.1016/S1470-2045(20)30594-5 |
|
| Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. | Mulder RL et al. | The Lancet Oncology 22, e57 – e67, 2021. https://doi.org/10.1016/S1470-2045(20)30582-9 |
|
| Communication and ethical considerations for fertility preservation for patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. | Mulder RL et al. | The Lancet Oncology 22, e68 – e80, 2021. https://doi.org/10.1016/S1470-2045(20)30595-7 |
|
| Managing a pan-European consortium on late effects among long-term survivors of childhood and adolescent cancer – the PanCareLIFE project. | Kaatsch P et al. | Int J Environ Res Public Health 2021, 18, 3918. https://doi.org/10.3390/ijerph18083918. |
|
| TCERG1L allelic variation is associated with cisplatin-induced hearing loss in childhood cancer, a PanCareLIFE study. | Meijer AJM et al. | NPJ Precision Oncology; 5:64: February 2021. https://doi.org/10.1038/s41698-021-00178-z |
|
| Fertility-Related Wishes and Concerns of Adolescent Cancer Patients and Their Parents. | Korte E et al. | J Adolesc Young Adult Oncol. 2020 Feb;9(1):55-62. https://doi.org/10.1089/jayao.2019.0064 |
|
| Fertility education for adolescent cancer patients: Gaps in current clinical practice in Europe. | Korte E et al. | Eur J Cancer Care 2020 Sep. Sep;29(5):e13279. https://doi.org/10.1111/ecc.13279 |
|
| Fertility knowledge and associated empowerment following an educational intervention for adolescent cancer patients. | Borgmann-Staudt A et al. | Psychooncology. 2019 Nov;28(11):2218-2225. https://doi.org/10.1002/pon.5210 |
|
| Determinants of utilization of cryopreservation of germ cells in adolescent cancer patients in four European countries. | Balcerek M et al. | Eur J Pediatr. 2020 Jan;179(1):51-60. https://doi.org/10.1007/s00431-019-03459-9 |